A Randomized Phase II Trial of Oral Topotecan Versus Docetaxel in the Second-Line Treatment of Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.3816/clc.2008.n.023 ◽

2008 ◽

Vol 9 (3) ◽

pp. 154-159 ◽

Author(s):

Suzanne Jones ◽

Dana Thompson ◽

John Barton ◽

Jeff Patton ◽

Dianna Shipley ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

Download Full-text

Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer

Investigational New Drugs ◽

10.1007/s10637-005-0754-6 ◽

2005 ◽

Vol 23 (6) ◽

pp. 563-567 ◽

Author(s):

Afshin Dowlati ◽

Robert Chapman ◽

Shanmuga Subbiah ◽

Pingfu Fu ◽

Anne Ness ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

Download Full-text

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer

Investigational New Drugs ◽

10.1007/s10637-012-9842-6 ◽

2012 ◽

Vol 31 (1) ◽

pp. 175-182 ◽

Author(s):

Christian Manegold ◽

Johan Vansteenkiste ◽

Felipe Cardenal ◽

Wolfgang Schuette ◽

Penella J. Woll ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

Integrin Inhibitor

Download Full-text

Phase II trial of prolonged infusion gemcitabine as second line treatment in non-small cell lung cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7316 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7316-7316

Author(s):

M. B. Kleinman ◽

I. Stewart ◽

S. Ratmanskiy ◽

M. Gayle ◽

P. Bonomi

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Prolonged Infusion

Download Full-text

A multicenter phase II trial with gemcitabine plus oxaliplatin as second line treatment in patients with advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7263 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7263-7263

Author(s):

C. Kouroussis ◽

K. Syrigos ◽

A. Potamianou ◽

N. Ziras ◽

P. Ziotopoulos ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Multicenter Phase

Download Full-text

Phase II trial of prolonged infusion gemcitabine as second line treatment in non-small cell lung cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.7316 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7316-7316

Author(s):

M. B. Kleinman ◽

I. Stewart ◽

S. Ratmanskiy ◽

M. Gayle ◽

P. Bonomi

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Prolonged Infusion

Download Full-text

A phase II trial of single-agent vinflunine as second-line treatment for advanced non-small cell lung cancer (An International Oncology Network Study, #I-05–009)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.19033 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 19033-19033 ◽

Author(s):

M. Joppert ◽

M. Knapp ◽

S. R. Dakhil ◽

R. V. Boccia ◽

R. Steis ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Single Agent ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung

Download Full-text

Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8061 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8061-8061 ◽

Author(s):

D. M. Kocs ◽

R. N. Raju ◽

M. A. Socinski ◽

T. E. Stinchcombe ◽

S. R. Rousey ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7576 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7576-7576 ◽

Author(s):

T. Stinchcombe ◽

D. S. Bradford ◽

C. B. Lee ◽

D. T. Moore ◽

K. M. Bakri ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7055 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7055-7055 ◽

Author(s):

D. M. Waterhouse ◽

S. K. Morgan ◽

D. R. Spigel ◽

S. Shankar ◽

B. Dharan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Study ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Download Full-text

Docetaxel + ramucirumab (DR) versus docetaxel + placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8054 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8054-8054 ◽

Author(s):

Yukio Hosomi ◽

Kiyotaka Yoh ◽

Kazuo Kasahara ◽

Kazuhiko Yamada ◽

Toshiaki Takahashi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Multicenter Trial ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Randomized Phase Ii

Download Full-text